Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

DSIP History — Research vs Clinical Comparison

The trajectory of DSIP from discovery to modern research reveals a compound that never transitioned cleanly from laboratory curiosity to therapeutic standard. The table below compares key aspects of DSIP research evolution, clinical trial outcomes, and current

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • The trajectory of DSIP from discovery to modern research reveals a compound that never transitioned cleanly from laboratory curiosity to therapeutic standard. The table below compares key aspects of DSIP research evolution, clinical trial outcomes, and current regulatory standing.
  • 1977–1980
  • EEG delta-wave modulation in animal models
  • Increased delta-wave amplitude in rats and rabbits; no effect on sleep latency or total sleep time
  • No human trials
  • Experimental only
  • 1981–1990
  • Human trials for insomnia, stress disorders, alcohol withdrawal (primarily Soviet and European research)
  • Subjective sleep improvement in some trials; stress biomarker reduction (cortisol, ACTH); inconsistent replication in Western labs
  • Limited adoption outside Eastern Europe
  • Not approved by FDA or EMA
  • 1991–2010
  • Mechanism of action studies; receptor identification efforts; analgesic and opioid modulation research
  • No specific DSIP receptor identified; evidence of opioid receptor interaction and stress-axis modulation; analgesic effects in chronic pain models
  • Minimal new clinical trials; existing trials not replicated to regulatory standards
  • Research-grade peptide; off-label compounding in some jurisdictions
  • 2011–2026
  • Modern peptide synthesis; bioavailability optimisation; HPA-axis and cortisol regulation studies
  • Improved stability with modified synthesis; confirmed interaction with opioid pathways; ongoing investigation of stress-protective mechanisms
  • No FDA-approved formulation; available as research peptide through 503B facilities like Real Peptides
  • Research use only; not approved for human therapeutic application
  • The table illustrates a persistent gap: DSIP has never progressed beyond Phase II-equivalent trials in Western regulatory frameworks. The majority of human data comes from trials conducted before 1995, and replication has been inconsistent. For researchers evaluating DSIP in 2026, this history matters. The peptide remains an investigational tool, not a validated therapeutic.

Related resources

More comparisons